Roble, Belko & Company, Inc Novartis Ag Transaction History
Roble, Belko & Company, Inc
- $634 Million
- Q3 2024
A detailed history of Roble, Belko & Company, Inc transactions in Novartis Ag stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 470 shares of NVS stock, worth $46,577. This represents 0.01% of its overall portfolio holdings.
Number of Shares
470
Previous 470
-0.0%
Holding current value
$46,577
Previous $50,000
8.0%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding NVS
# of Institutions
1,438Shares Held
133MCall Options Held
1.12MPut Options Held
1.83M-
Dodge & Cox San Francisco, CA12.2MShares$1.21 Billion0.85% of portfolio
-
Primecap Management CO Pasadena, CA12MShares$1.19 Billion1.03% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.09MShares$802 Million0.23% of portfolio
-
Morgan Stanley New York, NY6.98MShares$692 Million0.06% of portfolio
-
Loomis Sayles & CO L P5.77MShares$572 Million0.87% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $213B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...